Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
More Than 110 New Species Discovered In Deep Waters Off Australia- The 15 Best Business visionaries Under 40
- Astonishing Deserts All over The Planet You Really want To Visit
- The Electric Bicycle Americans Can Confide in 2024
- Report in relation to renaming Herzog Park set to be withdrawn
- Novo Nordisk gears up for December Ozempic launch in India, sources say
- April's full moon decides the date of Easter — here's how it works
- Sarkozy says he owes France 'the truth' as he challenges conviction over alleged Libya funding
- Dutch police probe a small blast outside a pro-Israel Christian center
